GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » BioTelemetry Inc (NAS:BEAT) » Definitions » Cash Ratio

BioTelemetry (BioTelemetry) Cash Ratio : 1.33 (As of Sep. 2020)


View and export this data going back to 2008. Start your Free Trial

What is BioTelemetry Cash Ratio?

The Cash Ratio measures a company’s ability to meet its short-term obligations with cash and near-cash resources. It is calculated as a company's Cash, Cash Equivalents, Marketable Securities divides by its Total Current Liabilities. BioTelemetry's Cash Ratio for the quarter that ended in Sep. 2020 was 1.33.

BioTelemetry has a Cash Ratio of 1.33. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.

The historical rank and industry rank for BioTelemetry's Cash Ratio or its related term are showing as below:

BEAT's Cash Ratio is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 1.05
* Ranked among companies with meaningful Cash Ratio only.

BioTelemetry Cash Ratio Historical Data

The historical data trend for BioTelemetry's Cash Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioTelemetry Cash Ratio Chart

BioTelemetry Annual Data
Trend Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19
Cash Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.79 0.73 0.71 1.63 1.23

BioTelemetry Quarterly Data
Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20
Cash Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.01 1.23 2.18 1.20 1.33

Competitive Comparison of BioTelemetry's Cash Ratio

For the Diagnostics & Research subindustry, BioTelemetry's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioTelemetry's Cash Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, BioTelemetry's Cash Ratio distribution charts can be found below:

* The bar in red indicates where BioTelemetry's Cash Ratio falls into.



BioTelemetry Cash Ratio Calculation

The Cash Ratio measures a company's ability to meet its short-term obligations with its cash and near-cash resources.

BioTelemetry's Cash Ratio for the fiscal year that ended in Dec. 2019 is calculated as:

Cash Ratio (A: Dec. 2019 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=68.614/55.754
=1.23

BioTelemetry's Cash Ratio for the quarter that ended in Sep. 2020 is calculated as:

Cash Ratio (Q: Sep. 2020 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=90.229/68.012
=1.33

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BioTelemetry  (NAS:BEAT) Cash Ratio Explanation

The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.

The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.

In general, the higher the cash ratio, the better the company's liquidity position.


BioTelemetry Cash Ratio Related Terms

Thank you for viewing the detailed overview of BioTelemetry's Cash Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


BioTelemetry (BioTelemetry) Business Description

Traded in Other Exchanges
N/A
Address
1000 Cedar Hollow Road, Suite 102, Malvern, PA, USA, 19355
BioTelemetry Inc provides monitoring services and digital population health management for healthcare providers, medical device manufacturing, and centralized core laboratory services for clinical research. It operates under healthcare, technology, and research segments. The Healthcare segment is focused on the diagnosis and monitoring of cardiac arrhythmias or heart rhythm disorders. The Research segment is engaged in central core laboratory services providing cardiac monitoring, imaging services, scientific consulting and data management services for drug and medical device trials and the Technology segment, focuses on the development, manufacturing, testing, and marketing of cardiovascular and blood glucose monitoring devices to medical companies, clinics and hospitals.
Executives
Kirk E Gorman director 367 SOUTH GULPH ROAD, KING PRUSSIA PA 19406
Stephen Rietiker director C/O BIOTELEMETRY, INC., 1000 CEDAR HOLLOW RD. SUITE 102, MALVERN PA 19355
Tiffany Olson director C/O CASTLE BIOSCIENCES, INC., 505 S. FRIENDSWOOD DRIVE, SUITE 401, FRIENDSWOOD TX 77546
Joseph A. Frick director ONE COMMERCE SQUARE 2005 MARKET ST., SUITE 3300 19103 PR 19073
Laura N. Dietch director 1000 CEDAR HOLLOW RD. SUITE 102 MALVERN PA 19355
Anthony James Conti director 76 GOLFVIEW DRIVE, IVYLAND PA 18974
Rebecca W Rimel director 345 PARK AVENUE, NEW YORK NY 10154
Robert J. Rubin director 7901 SPRINGER ROAD, BETHESDA MD 20817
Hill Colin director 196 BROADWAY CAMBRIDGE MA 02139
Andrei G Stoica officer: SVP & CTO 1000 CEDAR HOLLOW ROAD, MALVERN PA 19355
Joseph H Capper director, officer: President & CEO BIOTELEMETRY, INC., 1000 CEDAR HOLLOW ROAD, #102, MALVERN PA 19355
Manish Wadhwa officer: SVP & CMO 1000 CEDAR HOLLOW ROAD MALVERN PA 19355
Fred Broadway officer: President BioTel Heart BIOTELEMETRY, INC. 1000 CEDAR HOLLOW ROAD, #102 MALVERN PA 19355
Daniel Wisniewski officer: SVP, Technical Operations BIOTELEMETRY, INC. 1000 CEDAR HOLLOW ROAD, #102 MALVERN PA 19355
Heather C Getz officer: EVP, CFO & CAO BIOTELEMETRY, INC., 1000 CEDAR HOLLOW ROAD, #102, MALVERN PA 19355